What Happened? Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 7.5% in the morning session after ...

Shares of Charles River Laboratories International Inc. advanced 9.06% to $163.36 Tuesday, on what proved to be an all-around ...

Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit ...

This was the stock's third consecutive day of losses.

Business: Charles River Laboratories is an early-stage contract research company. The company engages in laboratory animal medicine and science (research model technologies), and it has developed ...

Charles River Laboratories International Inc. (NYSE: CRL), fresh from the collapse of a proposed, $1.6 billion merger with WuXi PharmaTech (Cayman) Inc. (NYSE: WX), plans to accelerate a $300 ...

Charles River isn’t the only CRO to have struggled in the third quarter. Irish firm Icon reported third-quarter revenue of $2.03 billion, underperforming analyst expectations of $2.14 billion ...

Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company’s quarterly revenue was down 2.7% compared to the same quarter last year.

Charles River Laboratories' share price has declined over 50% from its 2021 peak, presenting a potential buying opportunity for investors. The CRO company is facing headwinds from COVID's overhang ...

Charles River Laboratories International, Inc. today reported its results for the third quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 3.8% from $989.2 million in the ...

The stock price of Charles River Laboratories (NYSE:CRL), a company that offers clinical laboratory, gene therapy, and cell therapy services for the pharmaceuticals industry, has seen a 13% rise ...